Trace the timeline of CRISPR-Cas9 from its 2012 discovery to the latest AI-driven advancements and "N-of-1" clinical ...
Merck & Co. will apply the somatic genomics platform Quotient Therapeutics to discover novel drug targets in inflammatory bowel disease (IBD), through a collaboration that could generate up to $2.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results